ArticleJournal of orthopaedic research : official publication of the Orthopaedic Research Society2026
Stem Cells From Human Exfoliated Deciduous Teeth as a Potent Cell Therapy for Radiation-Induced Osteonecrosis Model.
Article in Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Osteonecrosis is a serious disorder leading to subchondral bone collapse and joint dysfunction. Osteonecrosis has been increasingly diagnosed before bone collapse; however, effective treatments for regenerating necrotic bone remain unavailable. Mesenchymal stem cell (MSC)-based therapies are promising; however, bone marrow-derived MSCs (BMSCs) are limited by donor burden, low yield, and suboptimal regenerative efficacy. Stem cells from human exfoliated deciduous teeth (SHED) exhibit higher proliferative capacity, enhanced growth factor secretion, minimal senescence, and noninvasive harvesting, making them a strong alternative. We evaluated SHED and BMSCs in a refractory rat model of radiation-induced tibial osteonecrosis. In vitro, SHED secreted similar or higher levels of proangiogenic and chemotactic factors-including vascular endothelial growth factor, angiopoietin-2, stem cell factor, monocyte chemoattractant protein-1, and C-C motif chemokine ligand 5-than BMSCs and significantly enhanced macrophage migration. Hydroxyapatite/collagen scaffolds seeded with SHED or BMSCs were transplanted into irradiated tibial bone defects in vivo. Micro-computed tomography revealed significantly accelerated bone regeneration with SHED, but not with BMSCs, compared with cell-free scaffolds. Histology confirmed new bone and marrow formation at SHED-treated sites, accompanied by increased periosteal proliferation and vascularity. Bulk RNA sequencing showed that SHED transplantation upregulated angiogenesis and immune cell recruitment-related pathways, whereas BMSCs upregulated genes associated with endochondral ossification without effective regeneration. Notably, SHED did not differentiate into osteoblasts or chondrocytes in vivo, indicating paracrine mediation of angiogenesis and macrophage recruitment. Given the limited regenerative capacity of necrotic bone, SHED's angiogenic and immunomodulatory activities position it as a promising candidate for cell-based therapy in refractory osteonecrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.